KDNY(Delisted)
Chinook Therapeutics·NASDAQ
--
--(--)
KDNY fundamentals
Chinook Therapeutics (KDNY) released its earnings on May 2, 2018: revenue was -- (YoY 0.00%), beat estimates; EPS was -- (YoY 0.00%), met estimates.
Revenue / YoY
--
0.00%
EPS / YoY
--
0.00%
Report date
May 2, 2018
EPS
Revenue
Revenue & Expenses
KDNY has released its 2023 Q2 earnings report, with revenue of 1.01M, reflecting a YoY change of 141.15%, and net profit of -66.94M, showing a YoY change of -77.82%. The Sankey diagram below clearly presents KDNY's revenue sources and cost distribution.
Key Indicators
Chinook Therapeutics (KDNY) key financial stats and ratios, covering profitability, financial health, and leverage.
Chinook Therapeutics (KDNY)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Chinook Therapeutics (KDNY)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Chinook Therapeutics (KDNY)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Chinook Therapeutics (KDNY) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Chinook Therapeutics (KDNY) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
